ALK and non-small cell lung carcinoma: Treatment with crizotinib, an ALK inhibitor and one of the earliest validated TKIs, results in an overall response rate of ~ 60% in patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) [2, 3].